Financhill
Sell
35

SPRY Quote, Financials, Valuation and Earnings

Last price:
$10.03
Seasonality move :
-5.05%
Day range:
$9.70 - $10.05
52-week range:
$6.66 - $18.90
Dividend yield:
0%
P/E ratio:
174.21x
P/S ratio:
6.91x
P/B ratio:
6.71x
Volume:
1.2M
Avg. volume:
1.6M
1-year change:
-21.64%
Market cap:
$991.5M
Revenue:
$89.1M
EPS (TTM):
-$0.81

Earnings Data

Next earnings date for SPRY
Mar 19
2026
Most recent earnings per share
-$0.52
Missed by $0.03
(Nov 10/2025)
Consensus Estimate
-$0.49
(Nov 10/2025)

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

SPRY Quarterly Earnings History

Date Quarter Revenue Forecast Actual Revenue Reported EPS Consensus EPS Beat/Miss
03/31/2026 Q1 $24.9M -- -- -$0.62 --
03/19/2026 Q4 $25.6M -- -- -$0.48 --
11/10/2025 Q3 $28.7M $32.5M -$0.52 -$0.49 -$0.03
08/13/2025 Q2 $13.8M $15.7M -$0.46 -$0.52 $0.06
05/08/2025 Q1 $7.5M $8M -$0.35 -$0.36 $0.02
03/20/2025 Q4 $15.9M $86.6M $0.51 -$0.12 $0.63
11/13/2024 Q3 $575K $2.1M -$0.20 -$0.14 -$0.06
08/06/2024 Q2 $666.7K $500K -$0.13 -$0.12 -$0.01
05/09/2024 Q1 -- -- -$0.11 -$0.11 $0.00
03/21/2024 Q4 -- -- -$0.07 -$0.13 $0.05
11/09/2023 Q3 -- -- -$0.16 -- --
08/10/2023 Q2 -- $10K -$0.18 -- --
05/15/2023 Q1 -- $20K -$0.16 -- --
12/31/2022 Q4 -- $1.3M $0.29 -- --
09/30/2022 Q3 -- $189K -$0.21 -- --
06/30/2022 Q2 -- $464K -$0.21 -- --
03/31/2022 Q1 -- $663K -$0.24 -- --
12/31/2021 Q4 -- -- -$0.67 -- --
09/30/2021 Q3 -- -- -$0.65 -- --
06/30/2021 Q2 -- -- -$0.70 -- --
03/31/2021 Q1 -- -- -$0.54 -- --
12/31/2020 Q4 -- -- -$0.38 -- --
09/30/2020 Q3 -- -- -$0.25 -- --
06/30/2020 Q2 -- -- -$0.19 -- --
03/31/2020 Q1 -- -- -$0.16 -- --
12/31/2019 Q4 -- -- -$0.21 -- --

ARS Pharmaceuticals, Inc. Earnings Questions

  • How Much did ARS Pharmaceuticals, Inc. Generate in Revenue Last Quarter?

    ARS Pharmaceuticals, Inc. reported $32.5M worth of top line sales in its most recent quarter.

  • Did ARS Pharmaceuticals, Inc. Beat Earnings Last Quarter?

    ARS Pharmaceuticals, Inc. announced earnings per share of -$0.52 which represents a miss of analyst forecast a -$0.49 per share.

  • Is ARS Pharmaceuticals, Inc. Profitable?

    ARS Pharmaceuticals, Inc. reported $24.3M that represents $0.25 per share over the last quarter.

  • What is the Analyst Consensus for ARS Pharmaceuticals, Inc. EPS Next Year?

    ARS Pharmaceuticals, Inc.'s earnings are forecast to decrease from $0.08 per share to -$1.80 per share next year representing a decrease of -1.93%.

  • When is ARS Pharmaceuticals, Inc.'s Earnings Date?

    ARS Pharmaceuticals, Inc.'s next earnings date is March 19, 2026.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How Big Will the SpaceX IPO Be?
How Big Will the SpaceX IPO Be?

Operated up to now as a private business, SpaceX will…

Where Will ISRG Stock Be in 5 Years?
Where Will ISRG Stock Be in 5 Years?

Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…

Is Kratos Stock a Good Investment?
Is Kratos Stock a Good Investment?

UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…

Stock Ideas

Buy
56
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 63x

Buy
61
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 37x

Buy
53
Is GOOG Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 30x

Alerts

Sell
40
BILL alert for Feb 7

Bill Holdings, Inc. [BILL] is up 37.11% over the past day.

Buy
75
PRLB alert for Feb 7

Proto Labs, Inc. [PRLB] is up 28.33% over the past day.

Sell
30
MSTR alert for Feb 7

Strategy, Inc. [MSTR] is up 26.08% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock